Regulations restricting the sale and supply of gonadotrophin-releasing hormone analogues

As previously announced, regulations have come into force to restrict the prescribing and supply of puberty suppressing hormones / gonadotrophin releasing hormone (GnRH) analogues to children and young people under 18 for the purposes of gender dysphoria / gender incongruence.

During the period of the emergency ban (currently from 3 June to 3 September 2024), no new patients under 18 will be allowed to begin use of these medicines for the purposes of puberty suppression in those experiencing gender dysphoria/incongruence, outside of designated specialist NHS services.

Children and young people under 18 already established on these medicines for these purposes can continue to receive these medicines from a UK-registered prescriber, but generally the prescriptions must be endorsed ‘SLS’ by the prescriber.

Children and young people under 18 already established on these medicines for these purposes cannot access these medicines using a prescription issued after 3 June 2024 by an EEA-or Swiss-registered prescriber.

Further information and FAQs can be found on our Gonadotrophin Releasing Hormone (GnRH) Prescription Regulations webpage.